Emanuela Dell’Aquila

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Silvia Cocca · 1 shared paper, 2025 · strength 0.24
   • Paper Pancreatic cancer: Future challenges and new perspectives for an early diagnosis. DOI 10.5306/wjco.v16.i2.97248↗
2. Helga Bertani · 1 shared paper, 2025 · strength 0.24
   • Paper Pancreatic cancer: Future challenges and new perspectives for an early diagnosis. DOI 10.5306/wjco.v16.i2.97248↗
3. Francesco Leone · 2 shared papers, 2017–2025 · strength 0.22
   • Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗
   • Paper Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? DOI 10.1016/j.critrevonc.2017.03.025↗
4. Federico Nichetti · 1 shared paper, 2025 · strength 0.16
   • Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗
5. Caterina Vivaldi · 1 shared paper, 2025 · strength 0.16
   • Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗
6. Elisa Giommoni · 1 shared paper, 2025 · strength 0.16
   • Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗
7. Silvia Bozzarelli · 1 shared paper, 2025 · strength 0.16
   • Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗
8. Francesca Bergamo · 1 shared paper, 2025 · strength 0.16
   • Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗
9. Ingrid Garajová · 1 shared paper, 2025 · strength 0.16
   • Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗
10. Ilario Giovanni Rapposelli · 1 shared paper, 2025 · strength 0.16
    • Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗
11. Carolina Sciortino · 1 shared paper, 2025 · strength 0.16
    • Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗
12. Gianluca Tomasello · 1 shared paper, 2025 · strength 0.16
    • Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗
13. Monica Niger · 1 shared paper, 2025 · strength 0.16
    • Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗
14. Lisa Salvatore · 1 shared paper, 2025 · strength 0.16
    • Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗
15. Daniele Santini · 2 shared papers, 2017–2020 · strength 0.16
    • Paper Prognostic and predictive factors in pancreatic cancer. DOI 10.18632/oncotarget.27518↗
    • Paper Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? DOI 10.1016/j.critrevonc.2017.03.025↗
16. Bruno Vincenzi · 1 shared paper, 2020 · strength 0.10
    • Paper Prognostic and predictive factors in pancreatic cancer. DOI 10.18632/oncotarget.27518↗
17. Giuseppe Tonini · 1 shared paper, 2020 · strength 0.10
    • Paper Prognostic and predictive factors in pancreatic cancer. DOI 10.18632/oncotarget.27518↗
18. Francesca Simionato · 1 shared paper, 2017 · strength 0.06
    • Paper Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? DOI 10.1016/j.critrevonc.2017.03.025↗
19. Mario Scartozzi · 1 shared paper, 2017 · strength 0.06
    • Paper Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? DOI 10.1016/j.critrevonc.2017.03.025↗
20. Francesco Giuliani · 1 shared paper, 2017 · strength 0.06
    • Paper Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? DOI 10.1016/j.critrevonc.2017.03.025↗
21. Oronzo Brunetti · 1 shared paper, 2017 · strength 0.06
    • Paper Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? DOI 10.1016/j.critrevonc.2017.03.025↗
22. Giuseppe Aprile · 1 shared paper, 2017 · strength 0.06
    • Paper Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? DOI 10.1016/j.critrevonc.2017.03.025↗
23. Davide Melisi · 1 shared paper, 2017 · strength 0.06
    • Paper Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? DOI 10.1016/j.critrevonc.2017.03.025↗
24. Nicola Silvestris · 1 shared paper, 2017 · strength 0.06
    • Paper Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? DOI 10.1016/j.critrevonc.2017.03.025↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.